|
Dec.2014 - HCV Advocate Newsletter
(Preview)
[url]http://www.hcvadvocate.org/news/newsLetter/2014/advocate1214.html#2[...
|
Cinnamon Girl
|
3
|
1170
|
|
|
|
|
Snapshots from AASLD 2014
(Preview)
Snapshots from AASLD 2014, by Lucinda K. Porter, RNLots of interesting reading here, for anyone interested. "December`s Snapshots typically features abstracts presented at the recent Liver Meeting. The research presented here was gathered from conference posters, presentations and abstr...
|
Cinnamon Girl
|
1
|
761
|
|
|
|
|
sumthing about Gillead on mainstream news website......
(Preview)
http://www.msn.com/en-us/money/insurance/costly-hepatitis-%E2%80%98c%E2%80%99-drug-makers-face-new-fire/ar-BBgkEi9
|
Josh Haynie
|
4
|
1067
|
|
|
|
|
Sovaldi will be available on Spain`s national health system, for those in most urgent need
(Preview)
The long-awaited new Hepatitis C drug (Sovaldi) will be available on Spain`s national health system shortly, but only for certain patients. According to Dr María Londoño from the Hospital Clínic in Barcelona, a member of the Spanish Agency for Medication and Healthcare Products, the drug Sovald...
|
Cinnamon Girl
|
2
|
1196
|
|
|
|
LA Times Grim News about HCV
(closed)
(Preview)
Fewer Americans are living with hepatitis C, because more have diedMarch 03, 2014|By Karen Kaplan Interesting sniptistics from the article: "Overall, 81% of all people with chronic hepatitis C were born between 1945 and 1965. This is why the CDC recommends that all people born during that wi...
|
Harvoninme
|
14
|
1612
|
|
|
|
|
Harvoni Scripts
(Preview)
Harvoni scripts were ~ 4,400 for last week in the USA. Averaged out that means only ~ 88 people per state were approved (and this was the highest week yet). That doesn't seem like many from a patient's point of view. BTW, I am beginning to HATE Pharma investors. They talk about these drugs as if they we...
|
Isiscat2011
|
8
|
1926
|
|
|
|
|
NY State poised to deny Hep C TX
(Preview)
http://www.vocal-ny.org/blog/new-york-state-poised-to-deny-hepatitis-c-treatment-to-thousands/
|
RudiRoo
|
8
|
1484
|
|
|
|
|
Daclatasvir Delayed
(Preview)
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C "Despite the recent advances in the treatment of hepatitis C there remain significant areas of unmet high need in this disease are...
|
Harvoninme
|
0
|
764
|
|
|
|
|
ABBVie & Europe
(Preview)
http://www.reuters.com/article/2014/11/21/us-europe-medicine-approvals-idUSKCN0J518920141121
|
Isiscat2011
|
1
|
1003
|
|
|
|
|
Harvoni Gets European Marketing Approval
(Preview)
http://www.fiercepharma.com/story/eu-nod-sets-gileads-harvoni-record-breaking-sales/2014-11-18 "But Europe, like the U.S., has already given some indication that it may have trouble affording the drug, which checks in at $94,500 per 12-week treatment cours...
|
Isiscat2011
|
0
|
916
|
|
|
|
|
BMS Schemes to Exclude Mid-Income Countries
(Preview)
http://blogs.wsj.com/pharmalot/2014/11/03/bristol-myers-plan-to-widen-access-to-its-hep-c-drug-but-meets-criticism/
|
Isiscat2011
|
1
|
1015
|
|
|
|
|
Real World S/O Results
(Preview)
http://www.ajmc.com/conferences/AASLD2014/The-Real-World-Experience-With-Simprevir-and-Sofosbuvir-Based-Regimens-in-Hep-C-Treatment
|
Isiscat2011
|
17
|
2396
|
|
|
|
|
How Docs Are Applying Guidelines
(Preview)
As we know the AASLD guidelines established a basis for who and when to treat. Despite the AASLD's subsequent statement that the guidelines were not intended to be used to deny tx the guidelines do in fact clearly set forth a type of rationing system. If you are wondering how docs in clinical practic...
|
Isiscat2011
|
0
|
867
|
|
|
|
|
Fibrosis Calculator
(Preview)
This is a calculator that supposedly calculates the degree of fibrosis (and other things) using your standard liver blood tests. I am not sure how accurate it is. I entered my numbers and it said that I have severe fibrosis or mild cirrhosis--which is accurate. Just thought I'd share it. Is i...
|
suziq
|
6
|
1622
|
|
|
|
|
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie $
(Preview)
Hey All AbbVie has been granted five US patents that specifically claim the use of Sofosbuvir and Ledipasvir, the drug combination that Gilead sales under the name of Harvoni. Check out the article Seeking alpha - http://www.seekingalpha.com/article/2674915 This will takes years of litigatio...
|
Matt Chris
|
6
|
1407
|
|
|
|
|
Gilead's New Triple?
(Preview)
Okay so I'm kicking myself because I read an awesome article this morning about Gilead's new Triple (6 week regimen) and can't find it now. The nuts and bolts were that Gilead is in the early clinical stages to test Harvoni combined with another drug called "Vedroprevir" and a small sample...
|
Fireman Rob
|
1
|
851
|
|
|
|
|
Some Perspective for Americans
(Preview)
Australia's rejection of costly new treatment sofosbuvir a 'death sentence for Hepatitis C sufferers'By Deborah Cornwall Liver experts at a conference on the Gold Coast have been warned Australia is on the verge of a catastrophic death spiral from Hepatitis C. Dr Miriam Levy, the director of gas...
|
Isiscat2011
|
2
|
1028
|
|
|
|
|
Merk four-week Hep C regimen with Sovaldi comes up short.
(Preview)
http://www.reuters.com/article/2014/11/10/us-merck-co-hepatitis-idUSKCN0IU00K20141110?feedType=RSS&feedName=healthNews
|
Lowrider
|
2
|
712
|
|
|
|
|
New Info on HCV
(Preview)
http://hepatitiscnewdrugresearch.com/2014-hepatitis-c---breaking-conference-reports.html-- Edit...
|
Isiscat2011
|
2
|
753
|
|
|
|
|
Olysio with Sovaldi: FDA approved
(Preview)
On May 7, 2014 the manufacturer of Olysio (Janssen) submitted a supplemental new drug application to use Olysio in combination with Sovaldi. Up until now the use of S/O has been off-label. I just got an email update from the FDA that indicates the FDA has approved the S/O combo. It states in pertinen...
|
Isiscat2011
|
5
|
1290
|
|
|
|
|
Maximizing SVR in the Real World
(Preview)
A recent article written by a doctor that is well worth the read: Delivering on the Promise: Maximizing SVR in the Real WorldJordan J. Feld, MD, MPH - 10/6/2014 More from this authorWith the promise of curing up to 75% of patients infected with genotype 1 HCV, the approval of the first-generatio...
|
Isiscat2011
|
1
|
1146
|
|
|
|
|
PBMs Showdown w/Gilead
(Preview)
The CEO of PBM Express Scripts has been very outspoken about Gilead's pricing. In the news (and on his blog) he is saying that Express Scripts may drop Harvoni from its formulary once Abbvie is approved assuming Abbvie is more reasonably priced. It appears the Insurance Cos and PBMs are sending a me...
|
Isiscat2011
|
5
|
1395
|
|
|
|
|
3 Die After Being Administered Sovriad (simeprevir sodium) Hepatitus C Drug
(Preview)
This is OLYSIO !Sunday, October 26, 2014Posted by HCV New DrugsFILE UNDERHCV NEWS, HCV WORLDWIDE,SIDE EFFECTS,SIMEPREVIR3 die after being administered hepatitis C drug The health ministry said Friday three people have died after taking the hepatitis C drug Sovriad, and it has ordered the dis...
|
Brownie
|
3
|
1368
|
|
|
|
|
Harvoni is ok for some pregnet women!! wow.
(Preview)
http://blogs.hepmag.com/lucindakporter/2014/10/harvoni_what_you_nee.html
|
Huey
|
0
|
1061
|
|
|
|
|
Charts linked in article comparing the current HCV meds
(Preview)
http://www.marketwired.com/press-release/move-over-gilead-abbvie-could-bring-serious-competition-to-hcv-market-1956910.htm
|
LC
|
2
|
896
|
|
|
|
|
Fair Pricing Coalition Urges Uniform Price for Curative Treatent
(Preview)
"While Gilead has contended that the total price for a course of treatment with a Sovaldi-containing regimen was a modest increase compared with previous standards of care, this is an invalid argument based on the incorrect premise that these regimens were appropriately priced to begin wit...
|
OldenSlow
|
0
|
783
|
|
|
|
|
hiv-hcv co-infection cure!!!
(Preview)
http://au.ibtimes.com/articles/569239/20141011/biotron-limited-asx-bit-hiv-cure-hepatitis.htm#.VDlTmSWP-EU
|
Huey
|
0
|
845
|
|
|
|
|
$94.5 K
(Preview)
Following FDA approval today of Harvoni, Gilead's newest--and first all-oral--treatment for hepatitis C, AHF and other drug pricing advocates, blasted the Bay Area drug maker for the $94,500 price for the drug, $125 above the $1,000 per pill Gilead currently charges for its current Sovaldi form...
|
Isiscat2011
|
14
|
1790
|
|
|
|
|
Medicaid Restrictions on Sovaldi
(Preview)
More states have enacted restrictions on Medicaid coverage of Sovaldi. The count is now up to 70% of states and can be expected to increase. Below is a state-by-state overview of those that have restrictions to limit the tx to the sickest. Expect to see similar prior authorization requirements fr...
|
Isiscat2011
|
3
|
755
|
|
|
|
|
BMS Withdraws New Drug Application for Asunaprevir
(Preview)
BMS has withdrawn its NDA for asunaprevir. As you may recall the BMS combo of asunaprevir/declatasvir was scheduled for approval in December. BMS does intend to pursue the approval of declatasvir alone, however. This is actually good news because Declatasvir has been used in combination with...
|
Isiscat2011
|
1
|
766
|
|
|
